Gottlieb Recognizes OTC Monograph Woes During Confirmation Hearing
This article was originally published in The Rose Sheet
FDA commissioner nominee Scott Gottlieb agreed that the OTC drug monographs constitute “a system that is in need of modernization” during his April 5 confirmation hearing before the Senate HELP Committee. HELP Democrats tested the FDA commissioner nominee’s willingness to “stand up to the administration” and probed potential conflicts of interest.
You may also be interested in...
Former FDA Commissioner Scott Gottlieb says OTC drug switch sponsors could expedite introduction of agency’s long-awaited proposed rule on switch NDAs by submitting applications. During CHPA webinar, he said innovation by industry guides agency in rulemaking.
"We believe that we're going to get this done," but "it's possible that ... language authorizing the collection of user fees is not included in this year's appropriation legislation," says Sen. Bob Casey during HELP Committee's confirmation hearing for FDA commissioner nominee Stephen Hahn.
Five former US FDA leaders and many stakeholder groups say Acting Commissioner Norman Sharpless should be the next permanent commissioner.